Watch the first video segment here
MIAMI, FL / ACCESS Newswire / October 9, 2025 / iTolerance, Inc. (“iTolerance” or the “Company”), an early-stage privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced the launch of its Patient Journey video series, with the release of the first segment featuring Sandra Cohen Kalter, recently appointed member to the Company’s Strategic Advisory Group and parent of a child with Type 1 Diabetes.
This video series is designed to shed light on the daily realities of patients, caregivers and family members of those living with Type 1 Diabetes. Through these real-life experiences, the series aims to increase awareness and highlight the urgent need for better treatment options for Type 1 Diabetes.
“We believe it’s critical to put a human face to the disease. The Patient Journey series gives a voice to those navigating the challenges of Type 1 Diabetes every single day. Their stories are not only deeply moving but they are also a driving force behind our mission to develop innovative, life-changing therapies for those living with Type 1 Diabetes,” commented Anthony Japour, Chief Executive Officer of iTolerance.
Each episode will spotlight a different perspective, from patients managing the daily burden of insulin therapy, to caregivers balancing support and advocacy, and families adjusting different aspects of their lives around the disease.
As part of the first segment, Mrs. Cohen Kalter shares about her son’s Type 1 Diabetes diagnosis, the impact it has on daily living, and how their family has come to engage with the Type 1 Diabetes community. Additionally, she shares about how she connected with iTolerance, why she believes in the Company’s potential cure for Type 1 Diabetes, and how a new treatment option would impact her son and the broader Type 1 Diabetes community.
Watch the first video segment featuring Mrs. Cohen Kalter here, and access future segments on the Patient Journey page of the Company’s website, www.itolerance.com.
About iTolerance, Inc.
iTolerance is a regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without requiring life-long immunosuppression. Leveraging its proprietary biotechnology-derived Streptavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic cadaveric and stem cell-derived pancreatic islets to potentially cure Type 1 diabetes. Utilizing iTOL-100 to induce local immune tolerance, the Company is developing its lead indication as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for treating liver failure by utilizing hepatocytes and iTOL-401 as a nanoparticle formulation for large organ transplants without the need for life-long immunosuppression. For more information, please visit itolerance.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.
All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, anticipated levels of revenues, future national or regional economic and competitive conditions, and difficulties in developing the Company’s platform technology. Consequently, forward-looking statements should be regarded solely as the Company’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. The Company cannot guarantee future results, events, levels of activity, performance or achievements. The Company does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.
Investor Contact
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
iTolerance@jtcir.com
Media Contact
Susan Roberts
T: 202.779.0929
sr@roberts-communications.com
SOURCE: iTolerance, Inc.
View the original press release on ACCESS Newswire
